Loading clinical trials...
Loading clinical trials...
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer
Conditions
Interventions
pTVG-AR
gm-csf
Locations
3
United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
University of Washington Seattle Cancer Care Alliance
Seattle, Washington, United States
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Start Date
August 24, 2015
Primary Completion Date
May 1, 2019
Completion Date
November 28, 2020
Last Updated
February 4, 2021
NCT06844383
NCT06594926
NCT06487507
NCT05919264
NCT07004582
NCT06257264
Lead Sponsor
University of Wisconsin, Madison
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions